TY - JOUR
T1 - Monitoring of s protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus
AU - Fukushi, Masaya
AU - Yoshinaka, Yoshiyuki
AU - Matsuoka, Yusuke
AU - Hatakeyama, Seisuke
AU - Ishizaka, Yukihito
AU - Kirikae, Teruo
AU - Sasazuki, Takehiko
AU - Miyoshi-Akiyama, Tohru
PY - 2012/11
Y1 - 2012/11
N2 - Severe acute respiratory syndrome coronavirus (SARS-CoV) is the etiological agent of SARS, a fatal pulmonary disorder with no effective treatment. We found that SARS-CoV spike glycoprotein (S protein), a key molecule for viral entry, binds to calnexin, a molecular chaperone in the endoplasmic reticulum (ER), but not to calreticulin, a homolog of calnexin. Calnexin bound to most truncated mutants of S protein, and S protein bound to all mutants of calnexin. Pseudotyped virus carrying S protein (S-pseudovirus)produced by human cells that were treated with small interfering RNA (siRNA) for calnexin expression (calnexin siRNAtreated ells) showed significantly lower infectivity than S-pseudoviruses produced by untreated and control siRNA-treated cells.S-pseudovirus produced by calnexin siRNA-treated cells contained S protein modified with N-glycan side chains differently from other two S proteins and consisted of two kinds of viral particles: those of normal density with little S protein and those of high density with abundant S protein. Treatment with peptide-N-glycosidase F (PNGase F), which removes all types of N-glycan side chains from glycoproteins, eliminated the infectivity of S-pseudovirus. S-pseudovirus and SARS-CoV produced in the presence of α-glucosidase inhibitors, which disrupt the interaction between calnexin and its substrates, showed significantly lower infectivity than each virus produced in the absence of those compounds. In S-pseudovirus, the incorporation of S protein into viral particles was obviously inhibited. In SARS-CoV, viral production was obviously inhibited. These findings demonstrated that calnexin strictly monitors the maturation of S protein by its direct binding, resulting in conferring infectivity on SARS-CoV.
AB - Severe acute respiratory syndrome coronavirus (SARS-CoV) is the etiological agent of SARS, a fatal pulmonary disorder with no effective treatment. We found that SARS-CoV spike glycoprotein (S protein), a key molecule for viral entry, binds to calnexin, a molecular chaperone in the endoplasmic reticulum (ER), but not to calreticulin, a homolog of calnexin. Calnexin bound to most truncated mutants of S protein, and S protein bound to all mutants of calnexin. Pseudotyped virus carrying S protein (S-pseudovirus)produced by human cells that were treated with small interfering RNA (siRNA) for calnexin expression (calnexin siRNAtreated ells) showed significantly lower infectivity than S-pseudoviruses produced by untreated and control siRNA-treated cells.S-pseudovirus produced by calnexin siRNA-treated cells contained S protein modified with N-glycan side chains differently from other two S proteins and consisted of two kinds of viral particles: those of normal density with little S protein and those of high density with abundant S protein. Treatment with peptide-N-glycosidase F (PNGase F), which removes all types of N-glycan side chains from glycoproteins, eliminated the infectivity of S-pseudovirus. S-pseudovirus and SARS-CoV produced in the presence of α-glucosidase inhibitors, which disrupt the interaction between calnexin and its substrates, showed significantly lower infectivity than each virus produced in the absence of those compounds. In S-pseudovirus, the incorporation of S protein into viral particles was obviously inhibited. In SARS-CoV, viral production was obviously inhibited. These findings demonstrated that calnexin strictly monitors the maturation of S protein by its direct binding, resulting in conferring infectivity on SARS-CoV.
UR - http://www.scopus.com/inward/record.url?scp=84869050218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869050218&partnerID=8YFLogxK
U2 - 10.1128/JVI.01250-12
DO - 10.1128/JVI.01250-12
M3 - Article
C2 - 22915798
AN - SCOPUS:84869050218
SN - 0022-538X
VL - 86
SP - 11745
EP - 11753
JO - Journal of Virology
JF - Journal of Virology
IS - 21
ER -